1. Home
  2. ZKH vs AURA Comparison

ZKH vs AURA Comparison

Compare ZKH & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZKH

ZKH Group Limited

HOLD

Current Price

$3.20

Market Cap

486.5M

Sector

N/A

ML Signal

HOLD

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

HOLD

Current Price

$6.43

Market Cap

396.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
AURA
Founded
1998
2007
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.5M
396.8M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
ZKH
AURA
Price
$3.20
$6.43
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$20.33
AVG Volume (30 Days)
211.9K
197.8K
Earning Date
11-20-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,236,195,501.00
N/A
Revenue This Year
$2.44
N/A
Revenue Next Year
$9.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$4.35
52 Week High
$4.03
$9.14

Technical Indicators

Market Signals
Indicator
ZKH
AURA
Relative Strength Index (RSI) 53.96 60.80
Support Level $2.93 $5.89
Resistance Level $3.49 $6.53
Average True Range (ATR) 0.18 0.33
MACD 0.02 0.10
Stochastic Oscillator 48.67 86.21

Price Performance

Historical Comparison
ZKH
AURA

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Share on Social Networks: